Cancer rates continue to skyrocket, and the overall survival rate for stage IV cancer patients in the United States is a grim 2.1 percent. Clearly, the extensive use of expensive - sometimes ineffective - toxins in conventional oncology protocols is a failing strategy. Even the few survivors of these harsh slash-and-burn treatments can have a dismal quality of life, suffering with ailments such as nerve damage, heart muscle disease, and liver and kidney failure.